cardiovascular agents

Summary

Summary: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.

Top Publications

  1. ncbi Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II
    C Riccioni
    Complex Unit of Angiology, Nuovo Regina Margherita Hospital, Rome, Italy
    Int Angiol 27:253-9. 2008
  2. ncbi European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by r
    Ian Graham
    Department of Cardiology, Adelaide and Meath Hospital, Dublin, Ireland
    Eur Heart J 28:2375-414. 2007
  3. doi Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in
    Martin B Leon
    Columbia University Medical Center, New York, New York 10032, USA
    JACC Cardiovasc Interv 3:1043-50. 2010
  4. ncbi Reproducibility of quantitative optical coherence tomography for stent analysis
    Nieves Gonzalo
    Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    EuroIntervention 5:224-32. 2009
  5. ncbi The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases
    Hua Cai
    Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    Trends Pharmacol Sci 24:471-8. 2003
  6. doi Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event
    Jean Dallongevillle
    Department of Epidemiology and Public Health, INSERM U744, Institut Pasteur de Lille, 1 rue du Pr Calmette, 59019 Lille, France
    Heart 96:1744-9. 2010
  7. doi Eplerenone in patients with systolic heart failure and mild symptoms
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
    N Engl J Med 364:11-21. 2011
  8. ncbi Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study
    Bernardo Cortese
    Interventional Cardiology Unit, Cardiovascular Department, Ospedale della Misericordia, Grosseto, Italy
    Heart 96:1291-6. 2010
  9. ncbi Adherence in heart failure in the elderly: problem and possible solutions
    Martje H L van der Wal
    Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
    Int J Cardiol 125:203-8. 2008
  10. ncbi Prostacyclin among prostanoids
    Ryszard J Gryglewski
    Jagiellonian Medical Research Centre, Krakow, Sławkowska 17, PL 31 016 Kraków, Poland
    Pharmacol Rep 60:3-11. 2008

Research Grants

  1. Organic Nitrate Metabolism, Tolerance and Action
    Ho Leung Fung; Fiscal Year: 2010
  2. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2005
  3. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2006
  4. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2004
  5. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2003
  6. Impact of Medicaid Policy on cardiovascular drug use and clinical outcomes
    Michael A Fischer; Fiscal Year: 2010
  7. Metabolomics Network for Drug Response Phenotype
    RIMA F KADDURAH DAOUK; Fiscal Year: 2010
  8. Metabolomics Network for Drug Response Phenotype
    Rima Kaddurah Daouk; Fiscal Year: 2009
  9. Engineered tissue-based, high-throughput compound profiling
    Vy Lam; Fiscal Year: 2009
  10. Engineered tissue-based, high-throughput compound profiling
    VICTORIYA ALEKSANDROVNA RUFANOVA; Fiscal Year: 2010

Detail Information

Publications321 found, 100 shown here

  1. ncbi Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II
    C Riccioni
    Complex Unit of Angiology, Nuovo Regina Margherita Hospital, Rome, Italy
    Int Angiol 27:253-9. 2008
    ..PLC is involved in cellular metabolism and is transformed into two active substances, free L-carnitine and propionyl-coenzyme A in the mitochondria, which take part in fatty acid transfer and in the citric acid cycle, respectively...
  2. ncbi European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by r
    Ian Graham
    Department of Cardiology, Adelaide and Meath Hospital, Dublin, Ireland
    Eur Heart J 28:2375-414. 2007
  3. doi Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in
    Martin B Leon
    Columbia University Medical Center, New York, New York 10032, USA
    JACC Cardiovasc Interv 3:1043-50. 2010
    ..The increased frequency of very late (>1 year) stent thrombosis (VLST) has raised concerns with regard to the safety of sirolimus-eluting stents and paclitaxel-eluting stents (PES)...
  4. ncbi Reproducibility of quantitative optical coherence tomography for stent analysis
    Nieves Gonzalo
    Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    EuroIntervention 5:224-32. 2009
    ..To assess the inter- and intra- observer reproducibility for strut count, strut apposition and strut tissue coverage measurements with optical coherence tomography (OCT)...
  5. ncbi The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases
    Hua Cai
    Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    Trends Pharmacol Sci 24:471-8. 2003
    ..Recently, efforts have been devoted to developing inhibitors of NAD(P)H oxidases that will provide useful experimental tools and might have therapeutic potential in the treatment of human diseases...
  6. doi Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event
    Jean Dallongevillle
    Department of Epidemiology and Public Health, INSERM U744, Institut Pasteur de Lille, 1 rue du Pr Calmette, 59019 Lille, France
    Heart 96:1744-9. 2010
    ..To compare gender-related lifestyle changes and risk factor management after hospitalisation for a coronary event or revascularisation intervention in Europe...
  7. doi Eplerenone in patients with systolic heart failure and mild symptoms
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
    N Engl J Med 364:11-21. 2011
    ..We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms...
  8. ncbi Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study
    Bernardo Cortese
    Interventional Cardiology Unit, Cardiovascular Department, Ospedale della Misericordia, Grosseto, Italy
    Heart 96:1291-6. 2010
    ..The impact of a PCB during PCI of small coronary vessels was evaluated and compared to one of the most widely used DES...
  9. ncbi Adherence in heart failure in the elderly: problem and possible solutions
    Martje H L van der Wal
    Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
    Int J Cardiol 125:203-8. 2008
    ..Non-adherence to this regimen is a problem in many heart failure patients, leading to worsening symptoms, rehospitalization and decreased quality of life...
  10. ncbi Prostacyclin among prostanoids
    Ryszard J Gryglewski
    Jagiellonian Medical Research Centre, Krakow, Sławkowska 17, PL 31 016 Kraków, Poland
    Pharmacol Rep 60:3-11. 2008
    ..In this way, the foundations for the Endothelial Pharmacology were laid...
  11. ncbi 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to devel
    Theodore D Fraker
    Circulation 116:2762-72. 2007
  12. pmc Medication adherence: a call for action
    Hayden B Bosworth
    Center for Health Services Research in Primary Care, Durham VAMC, Durham, NC, USA
    Am Heart J 162:412-24. 2011
    ..We then summarize proven effective approaches and conclude with a discussion of recommendations to address this growing and significant public health issue of medication nonadherence...
  13. ncbi Patient and general practitioner attitudes to healthy lifestyle behaviours and medication following coronary heart disease: an exploratory study
    Catherine Speechly
    Projects, Research and Development Unit, RACGP NSW and ACT Faculty, 12 Mount Street, North Sydney, NSW 2060, Australia
    Aust J Prim Health 16:154-8. 2010
    ....
  14. ncbi ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise th
    Jeffrey L Anderson
    J Am Coll Cardiol 50:e1-e157. 2007
  15. doi Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic End
    Martin B Leon
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10032, USA
    JACC Cardiovasc Interv 2:1208-18. 2009
    ..The aim of this study was to assess, after 2 years of follow-up, the safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent (ZES) compared with a paclitaxel-eluting stent (PES) in patients with native coronary lesions...
  16. doi Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary
    Eric L Eisenstein
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    JACC Cardiovasc Interv 2:1199-207. 2009
    ....
  17. doi Controversies in cardiovascular medicine: Chronic stable coronary artery disease: drugs vs. revascularization
    Maarten L Simoons
    Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur Heart J 31:530-41. 2010
    ..Accordingly, CABG and PCI should be considered a valuable adjunct rather than an alternative to medical therapy...
  18. doi Comparison of zotarolimus- versus everolimus-eluting stents in the treatment of coronary bifurcation lesions
    Juan A Herrador
    Unidad de Hemodinamica, Servicio de Cardiologia, Complejo Hospitalario de Jaen, Spain
    Catheter Cardiovasc Interv 78:1086-92. 2011
    ..To compare zotarolimus-eluting stent (Endeavor Sprint®; ZES-S) and the everolimus-eluting stent (Xience V®; EES) in the treatment of coronary bifurcation lesions...
  19. ncbi Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction
    Angelo A Izzo
    Department of Experimental Pharmacology, University of Naples Federico II, via D Montesano 49, 80131 Naples, Italy
    Int J Cardiol 98:1-14. 2005
    ..John's wort. Interaction between herbal medicine and cardiovascular drugs is a potentially important safety issue. Patients taking anticoagulants are at the highest risk...
  20. ncbi Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial
    Christopher D Gardner
    Stanford Prevention Research Center and the Department of Medicine, Stanford University Medical School, Stanford, California, USA
    Blood Coagul Fibrinolysis 18:787-93. 2007
    ..No adverse bleeding events were observed, although the trial was limited to a small sample size...
  21. doi Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first
    Juan Luis Gutiérrez-Chico
    Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    EuroIntervention 7:711-22. 2011
    ..To test the efficacy of sequential application of drug-coated balloon (DCB) and bare metal stent (BMS) for treatment of de novo coronary lesions, comparing the sequence of application (DCB first vs. BMS first)...
  22. doi A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of th
    Pieter R Stella
    Department of Cardiology, University Medical Center Utrecht, Heidelberglaan 100, Room E 01 207, 3584 CX, Utrecht, The Netherlands
    Catheter Cardiovasc Interv 80:1138-46. 2012
    ..We compared angiographic and clinical outcomes of a provisional T-stenting technique with a DEB plus bare-metal stent (BMS) versus BMS versus paclitaxel DES...
  23. ncbi Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries
    Aniko Posa
    Department of Cardiology, Medical University of Vienna, Austria
    Catheter Cardiovasc Interv 76:395-403. 2010
    ....
  24. ncbi Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial
    Ameet Bakhai
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    J Am Coll Cardiol 48:253-61. 2006
    ....
  25. ncbi Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment
    Leong Lee
    Department of Cardiology, University of Nottingham, Queens Medical Centre, Nottingham, England
    Circulation 112:3280-8. 2005
    ..Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We assessed the effects of perhexiline treatment in CHF patients...
  26. ncbi Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials
    Shuzou Tanimoto
    Department of Interventional Cardiology, Thorax Center, Erasmus MC, Rotterdam, The Netherlands
    Catheter Cardiovasc Interv 70:515-23. 2007
    ..This study sought to evaluate and compare in vivo acute stent recoil of a novel bioabsorbable stent and a metallic stent...
  27. pmc Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
    Giorgia De Berardis
    Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8 A, 66030 S Maria Imbaro, Italy
    BMJ 339:b4531. 2009
    ..To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease...
  28. ncbi Drug-eluting stent fracture: incidence, contributing factors, and clinical implications
    Timothy Canan
    Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles, California, USA
    Catheter Cardiovasc Interv 75:237-45. 2010
    ..Other complications observed with stent fracture include stent thrombosis, coronary aneurysms, myocardial infarction, and sudden death...
  29. ncbi Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis
    Demosthenes G Katritsis
    Department of Cardiology, Athens Euroclinic, Athens, Greece
    Circulation 111:2906-12. 2005
    ..Therefore, we performed a meta-analysis of 11 randomized trials comparing PCI to conservative treatment in patients with stable CAD...
  30. pmc NO/redox disequilibrium in the failing heart and cardiovascular system
    Joshua M Hare
    Johns Hopkins University School of Medicine, Department of Medicine, Cardiology Division, Baltimore, Maryland 21205, USA
    J Clin Invest 115:509-17. 2005
    ....
  31. ncbi Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches
    Kelly L Miller
    Division of General Internal Medicine, Durham, NC, USA
    Am Heart J 147:401-11. 2004
    ....
  32. ncbi Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial
    Bruce L Wilkoff
    The Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F 15, Cleveland, OH 44195, USA
    JAMA 288:3115-23. 2002
    ..Most currently implanted ICD devices provide dual-chamber pacing therapy. The most common comorbid cause for mortality in this population is congestive heart failure...
  33. ncbi Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease
    J Virtamo
    National Public Health Institute, Helsinki, Finland
    Arch Intern Med 158:668-75. 1998
    ..Oxidized low-density lipoprotein is involved in the pathogenesis of atherosclerosis. In epidemiological studies antioxidants have been inversely related with coronary heart disease. Findings from controlled trials are inconclusive...
  34. ncbi The challenge of polypharmacy in cardiovascular medicine
    Massimo Volpe
    Cardiology Department, IInd School of Medicine, University of Rome Sapienza, S Andrea Hospital, Rome, Italy
    Fundam Clin Pharmacol 24:9-17. 2010
    ..However, large randomized trials are required to define its impact on clinical outcomes. This review will focus on challenges of polypharmacy in CV medicine, illustrating potential options to face this emerging crisis...
  35. ncbi Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
    Karl Swedberg
    Sahlgrenska Academy at the Göteborg University, Department of Medicine, Sahlgrenska University Hospital, Sweden
    Eur Heart J 26:1115-40. 2005
  36. ncbi Treatment of patent ductus arteriosus
    Jonathan Wyllie
    The James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW, UK
    Semin Neonatol 8:425-32. 2003
    ..PDA closure can then be achieved using medical means, with surgery reserved for patients in whom this fails or in whom there are contra-indications. However, the optimum timing for intervention remains unknown...
  37. ncbi A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial
    Raul Moreno
    University Hospital La Paz, Madrid, Spain
    EuroIntervention 6:112-6. 2010
    ..The primary endpoint will be angiographic in-stent late loss...
  38. doi Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation
    Christian Herdeg
    Medizinische Klinik III, Eberhard Karls Universitat Tubingen, Germany
    Circ Cardiovasc Interv 2:294-301. 2009
    ..We assessed the safety and efficacy of catheter-based local delivery of fluid paclitaxel in patients with coronary de novo stenoses after implantation of a bare metal stent...
  39. ncbi Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD)
    H Shigematsu
    Department of Vascular Surgery, Tokyo Medical University, Shinjuku ku, Tokyo, Japan
    Int Angiol 29:2-13. 2010
    ..To investigate the current status of peripheral arterial disease (PAD) drug treatment in Japan, and the effects of drug treatment, risk factors, and complications on disease progress and onset of cardiovascular events in PAD patients...
  40. doi Paclitaxel-eluting balloon: from bench to bed
    Axel de Labriolle
    Department of Internal Medicine, Division of Cardiology, Washington Hospital Center, Washington, DC, USA
    Catheter Cardiovasc Interv 73:643-52. 2009
    ..We aimed to review the concept, preclinical-, and clinical data available with non-stent based local drug delivery and, in particular, with paclitaxel-eluting balloons...
  41. doi A retrospective, observational cohort analysis of a nationwide database to compare heart failure prescriptions and related health care utilization before and after publication of updated treatment guidelines in the United States
    Shirin Shafazand
    Division of Pulmonary and Critical Care Medicine, University of Miami, Miller School of Medicine, Miami, Florida, USA
    Clin Ther 32:1642-50. 2010
    ....
  42. doi Gender differences in evidence-based pharmacological therapy for patients with stable coronary heart disease
    Carlos Lahoz
    Hospital Carlos III, Madrid, Spain
    Int J Cardiol 133:336-40. 2009
    ..We analyzed the prescription rates of evidence-based pharmacological therapies for patients with stable coronary heart disease and whether there were any differences with respect to gender...
  43. ncbi Antimicrobial potentiality of a new non-antibiotic: the cardiovascular drug oxyfedrine hydrochloride
    Kaushiki Mazumdar
    Division of Microbiology, Department of Pharmaceutical Technology, Jadavpur University, Calcutta 700 032, India
    Microbiol Res 158:259-64. 2003
    ..The in vivo results were highly significant according to chi-square test...
  44. ncbi Paclitaxel-induced arterial wall toxicity and inflammation: tissue uptake in various dose densities in a minipig model
    Boris Radeleff
    Department of Radiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
    J Vasc Interv Radiol 21:1262-70. 2010
    ..Toxicity might result from overdosage and/or accumulation. Part 1 of this two-step study investigated how paclitaxel uptake depends on dose density, coronary drug transfer kinetics, and elution efficacy...
  45. doi Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach
    Francesco Burzotta
    Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy
    JACC Cardiovasc Interv 4:327-35. 2011
    ..This study sought to compare the procedural performance and the acute angiographic result on side-branch ostium obtained using 2 different drug-eluting stents (DES) to treat patients with bifurcated coronary lesions...
  46. doi Late restenosis following sirolimus-eluting stent implantation
    Nehiro Kuriyama
    Department of Cardiology, Miyazaki Medical Association Hospital, Miyazaki, Japan
    JACC Cardiovasc Interv 4:123-8. 2011
    ..This serial angiographic study evaluated the incidence and predictors of late restenosis after sirolimus-eluting stent (SES) implantation...
  47. doi Effectiveness of guideline-recommended cardiac drugs for reducing mortality in the elderly medicare heart failure population: a retrospective, survey-weighted, cohort analysis
    Diane M Richardson
    Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA
    Drugs Aging 27:845-54. 2010
    ..However, the results of randomized controlled trials may not be generalizable to the population most likely (i.e. the elderly) to receive these drugs in clinical practice...
  48. doi Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: two-year follow-up from the E-Five Registry
    Ian Meredith
    MonashHeart, Monash Medical Centre and University, Melbourne, Australia
    Catheter Cardiovasc Interv 77:993-1000. 2011
    ..To present data from the cohort of patients in the all-comers Endeavor zotarolimus-eluting stent (ZES) registry (E-Five) who underwent 2-year follow-up...
  49. doi Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus
    Rosli Mohd Ali
    National Heart Institute, Kuala Lumpur, Malaysia
    EuroIntervention 7:K83-92. 2011
    ..Encouraging clinical data of the drug-eluting balloon catheter (DEB) SeQuent Please warrant its investigation in these patients...
  50. doi Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study
    Claudius Jacobshagen
    Department of Cardiology and Pneumology, Georg August University, Robert Koch Strasse 40, Gottingen, Germany
    Clin Cardiol 34:426-32. 2011
    ..So far, there has been no specific treatment for impaired left ventricular (LV) relaxation. Data from in vitro and animal studies indicate that ranolazine improves diastolic function by inhibiting the late sodium current...
  51. doi Three-year outcome of sirolimus-eluting stent implantation in coronary bifurcation lesions: the provisional side branch stenting approach versus the elective two-stent approach
    Toshihiro Tamura
    Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    EuroIntervention 7:588-96. 2011
    ..To explore optimal management strategies for bifurcation lesions with sirolimus-eluting stents (SES)...
  52. doi Flavanol-rich cocoa ameliorates lipemia-induced endothelial dysfunction
    Sabine Westphal
    Institute of Clinical Chemistry, Magdeburg University Hospital, Leipziger Str 44, 39120 Magdeburg, Germany
    Heart Vessels 26:511-5. 2011
    ..Flavanols did not have any influence on triglycerides or on free fatty acids. Flavanol-rich cocoa can alleviate the lipemia-induced endothelial dysfunction, probably through an improvement in endothelial NO synthase...
  53. doi Aneurysm formation after drug-eluting balloon treatment of drug-eluting in-stent restenosis: first case report
    Dobrin Vassilev
    Cardiac Catheterization Laboratory, National Heart Hospital, Sofia, Bulgaria
    Catheter Cardiovasc Interv 80:1223-6. 2012
    ..The patient was left on double antiplatelet therapy and scheduled for clinical observation after 3 months and control coronary angiography after 6 months for aneurysm progression follow-up...
  54. ncbi Studies on the antimicrobial potential of the cardiovascular drug lacidipine
    Asish Dasgupta
    Department of Pharmaceutical Technology, Jadavpur University, Calcutta 700 032, India
    In Vivo 21:847-50. 2007
    ..typhimurium NCTC 74. According to the chi-square test, the in vivo data were highly significant (p<0.001)...
  55. doi Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial
    Alexandra J Lansky
    Yale University School of Medicine, New Haven, CT 06520, USA
    EuroIntervention 6:J44-52. 2010
    ..Side branch occlusion was defined as Thrombolysis In Myocardial Infarction (TIMI) flow grade 0 or 1. Clinical outcomes through three years were compared by stent type and presence of side branch occlusion...
  56. doi Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society joint guidelines
    Michael McGillion
    University of Toronto, Toronto, Ontario, Canada
    Can J Cardiol 28:S20-41. 2012
    ..Concluding summary recommendations are also made, giving direction to future clinical practice and research on RFA management in Canada...
  57. doi Coronary pseudoaneurysm in a non-polymer drug-eluting stent: a rare entity
    Aditya Kapoor
    Department of Cardiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow
    Asian Cardiovasc Thorac Ann 19:407-10. 2011
    ..We describe a case of coronary pseudoaneurysm developing with a non-polymer-based drug-eluting stent in a 50-year-old man who was successfully managed by coronary artery bypass grafting...
  58. doi Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease
    Claudio Allegra
    San Giovanni Hospital, Rome, Italy
    Ann Vasc Surg 22:552-8. 2008
    ..From these preliminary data has emerged an indication of therapy with PLC for chronic obstructive arteriopathy of the lower limbs at stage II. Further studies with higher numbers of patients and more controlled variables are planned...
  59. ncbi Methods for identifying cardiovascular agents: a review
    David Anthony Tulis
    Cardiovascular Disease Research Program, J L Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA
    Recent Pat Cardiovasc Drug Discov 1:47-56. 2006
    ..The invention disclosed in Methods for identifying cardiovascular agents [1] provides screening methods which can be used to identify certain suspected cardiovascular agents that ..
  60. ncbi Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study
    Chiara Melloni
    Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Expert Rev Cardiovasc Ther 6:9-16. 2008
    ....
  61. ncbi Ranolazine (Ranexa) in the treatment of chronic stable angina
    Sajid Aslam
    Division of Cardiovascular Medicine, University Hospital, Nottingham, UK
    Adv Ther 27:193-201. 2010
    ..This review provides an insight into this treatment option, describes the clinical trials evidence, proposed mechanism of action, and pharmacokinetics, and outlines the indications for its use in chronic stable angina...
  62. ncbi Telmisartan prevents cardiovascular events in a broad group of at-risk patients
    Magnus Baumhakel
    University Hospital of the Saarland, Department of Cardiology, Homburg Saar, Germany
    Expert Opin Pharmacother 10:3113-7. 2009
    ..In these patients who are intolerant to ACE-Is or who do not achieve blood pressure control, the ARB with the best evidence for secondary prevention is telmisartan according to the results of the ONTARGET trial...
  63. ncbi Pharmacological activity of cardiovascular agents from herbal medicine
    John W Ho
    Department of Biochemistry, The Chinese University of Hong Kong, Shatin, Hong Kong
    Cardiovasc Hematol Agents Med Chem 5:273-7. 2007
    ..The study will provide insights into drug action and demonstrate the therapeutic benefits of herbal medicine for the treatment of cardiovascular disease...
  64. ncbi Systems biology approaches to the study of cardiovascular drugs
    Yuri Nikolsky
    GeneGo, Inc, St Joseph, MI, USA
    Methods Mol Biol 662:221-43. 2010
    ..All relevant steps, for example, experimental design, tissue collection and high quality RNA preparation, bioinformatical analysis of functional processes, and pathways (targeted and untargeted) are addressed...
  65. ncbi Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography
    Rory Hachamovitch
    Department of Imaging, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, Calif 90048, USA
    Circulation 107:2900-7. 2003
    ....
  66. ncbi Ranolazine: a review of its use in chronic stable angina pectoris
    M Asif A Siddiqui
    Adis International Limited, Auckland, New Zealand
    Drugs 66:693-710. 2006
    ..Nevertheless, ranolazine ER may well prove to be a useful alternative and adjunct to conventional haemodynamic antianginal therapy in the treatment of chronic stable angina...
  67. doi Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study
    Stefan Störk
    Department of Internal Medicine I Center for Cardiovascular Medicine, University of Wurzburg, Klinikstrasse 6 8, D 97070 Wurzburg, Germany
    Eur J Heart Fail 10:1236-45. 2008
    ..The effectiveness of chronic heart failure (CHF) pharmacotherapy in unselected cohorts is unknown...
  68. ncbi Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial
    Ian T Meredith
    Monash Heart Monash Medical Centre and University, Melbourne, Australia
    JACC Cardiovasc Interv 2:977-85. 2009
    ..The RESOLUTE trial examined the safety and efficacy of a next-generation zotarolimus-eluting coronary stent, Resolute (Medtronic CardioVascular Inc., Santa Rosa, California)...
  69. ncbi Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial
    Marie Claude Morice
    Institut Cardiovasculaire Paris Sud, Massy, France
    JAMA 295:895-904. 2006
    ....
  70. ncbi Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial
    Keiichi Tsuchida
    Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    Catheter Cardiovasc Interv 67:188-97. 2006
    ..05). Our proposed QCA volumetric measurements may be a practical surrogate for IVUS measurements and a discriminant methodological approach for assessment of treatment effects of drug-eluting stents...
  71. ncbi ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999
    Elliott M Antman
    Circulation 110:588-636. 2004
  72. ncbi The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment
    M Komajda
    Eur Heart J 24:464-74. 2003
    ..Accordingly, the Euro Heart Failure Survey was conducted to ascertain how patients hospitalized for heart failure are managed in Europe and if national variations occur in the treatment of this condition...
  73. doi Acute myocardial infarction associated with pregnancy
    Arie Roth
    Department of Cardiology Tel Aviv Sourasky Medical Center, Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel
    J Am Coll Cardiol 52:171-80. 2008
    ....
  74. ncbi Self-reported Morisky score for identifying nonadherence with cardiovascular medications
    Stephen J Shalansky
    Pharmacy Department, St Paul s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Ann Pharmacother 38:1363-8. 2004
    ..The Morisky medication adherence scale is a commonly used adherence screening tool. It is composed of 4 yes/no questions about past medication use patterns and is thus quick and simple to use during drug history interviews...
  75. ncbi Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management
    Colin Berry
    Department of Medicine, Montreal Heart Institute and Universite de Montreal, Montreal, Quebec, Canada
    J Am Coll Cardiol 49:631-42. 2007
    ..Noncompliance, particularly with lifestyle measures, and underprescription of evidence-based therapies remain important unsolved problems...
  76. ncbi Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Boston, Mass, USA
    JAMA 297:1319-31. 2007
    ..Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure...
  77. ncbi The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease
    Justin Ezekowitz
    Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada T6G 2R7
    J Am Coll Cardiol 44:1587-92. 2004
    ..This study was designed to examine the use of cardiovascular medications and outcomes in patients with heart failure (HF) and renal dysfunction...
  78. ncbi Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival
    Marc Michael Zaruba
    Klinikum der Ludwig Maximilians Universität München Grosshadern, Med Klinik und Poliklinik I, Marchioninistr 15, Munich, Germany
    Cardiovasc Res 77:722-31. 2008
    ..Therefore, we analysed in a murine model of experimental myocardial infarction (MI) the influence of PTH treatment on survival, functional parameters, stem cell migration, and expression of vascular endothelial growth factor A (VEGF-A)...
  79. pmc Associations of kidney function with cardiovascular medication use after myocardial infarction
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02120, USA
    Clin J Am Soc Nephrol 3:1415-22. 2008
    ..It is unknown whether adherence to recommended medications after myocardial infarction (MI) differs by kidney function...
  80. doi Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial
    Bimmer E Claessen
    Department of Cardiology, Academic Medical Center, University of Amsterdam, The Netherlands
    Circ Cardiovasc Interv 2:339-47. 2009
    ..This article reports the 2-year clinical, angiographic, and intravascular ultrasound outcomes of the everolimus-eluting stent (EES) compared with the paclitaxel-eluting stent (PES) in the randomized SPIRIT II trial...
  81. pmc Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial
    Jean Claude Tardif
    Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada
    Eur Heart J 30:540-8. 2009
    ..To evaluate the anti-anginal and anti-ischaemic efficacy of the selective I(f) current inhibitor ivabradine in patients with chronic stable angina pectoris receiving beta-blocker therapy...
  82. ncbi Suboptimal use of cardioprotective drugs in newly treated elderly individuals with type 2 diabetes
    Caroline Sirois
    Faculty of Pharmacy, Laval University, Quebec, Canada
    Diabetes Care 30:1880-2. 2007
  83. ncbi Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina
    Jean Claude Tardif
    Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada
    Eur Heart J 26:2529-36. 2005
    ..Ivabradine has shown anti-ischaemic and anti-anginal activity in a placebo-controlled trial. The objective of this study was to compare the anti-anginal and anti-ischaemic effects of ivabradine and the beta-blocker atenolol...
  84. ncbi 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to devel
    Theodore D Fraker
    J Am Coll Cardiol 50:2264-74. 2007
  85. ncbi Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine
    Markus Jerling
    Clinical Pharmacology, CV Therapeutics, Palo Alto, CA, USA
    Clin Pharmacol Ther 78:288-97. 2005
    ..No serious adverse events were observed in the study...
  86. ncbi Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients
    Lubomir Elbl
    Department of Cardiology, University Hospital Brno, Jihlavska 20, 62500 Brno, Czech Republic
    Eur J Pediatr 164:678-84. 2005
    ..A higher number of patients in the dexrazoxane group had very good exercise tolerance (ET) >3 Watts/kg ( P <0.05) and a lower number responded with a decreased ET <2 Watts/kg ( P <0.05) compared to the no-dexrazoxane group...
  87. ncbi Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial
    David A Morrow
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Mass 02115, USA
    JAMA 297:1775-83. 2007
    ..Ranolazine is a novel antianginal agent that reduces ischemia in patients with chronic angina but has not been studied in patients with acute coronary syndromes (ACS)...
  88. doi Aspirin for prevention of cardiovascular events
    William R Hiatt
    BMJ 337:a1806. 2008
  89. ncbi Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force
    John McB Hodgson
    St Joseph s Hospital and Medical Center, 350 West Thomas Road, Phoenix, AZ 85013, USA
    Catheter Cardiovasc Interv 69:327-33. 2007
  90. ncbi Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease
    Bart Staels
    Department of Atherosclerosis, Institut Pasteur de Lille, UMR545 Inserm, University of Lille 2, Lille, France
    Nat Clin Pract Cardiovasc Med 5:542-53. 2008
    ....
  91. ncbi Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patients
    Ali Hamaad
    University Department of Medicine, City Hospital, Dudley Road, Birmingham, England, UK
    Cardiovasc Drugs Ther 20:359-64. 2006
    ..To determine the effects of n3-PUFA supplementation, in the dose used in the GISSI-Prevenzione study, on indices of heart rate variability (HRV) in patients following myocardial infarction (AMI)...
  92. ncbi Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction
    Eric Bates
    Duke Clinical Research Institute, 2400 Pratt St, Room 7035, Durham, NC 27705
    Circulation 117:886-96. 2008
    ..KAI-9803, a delta-protein kinase C inhibitor, has been shown to ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI)...
  93. doi Stent fracture, an incidental finding or a significant marker of clinical in-stent restenosis?
    Fareed Shaikh
    Cardiovascular Disease Section, Aurora Sinai Aurora St Luke s Medical Centers, University of Wisconsin School of Medicine and Public Health Milwaukee Clinical Campus, Milwaukee, Wisconsin, USA
    Catheter Cardiovasc Interv 71:614-8. 2008
    ..The predictors and clinical significance for stent fracture (SF) in drug-eluting stents (DES) remain unknown. We identified procedural factors leading to SF and its clinical consequences in DES...
  94. pmc Neuropsychiatric consequences of cardiovascular medications
    Jeff C Huffman
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Dialogues Clin Neurosci 9:29-45. 2007
    The use of cardiovascular medications can have a variety of neuropsychiatric consequences. Many cardiovascular agents cause higher rates of fatigue and sedation than placebo, and case reports of medication-induced mood syndromes, ..
  95. ncbi Metabolic therapeutics in angina pectoris: history revisited with perhexiline
    Sally Inglis
    Faculty of Health Sciences, University of Queensland, Australia
    Eur J Cardiovasc Nurs 5:175-84. 2006
    ..This review aims to update the cardiac nurse with knowledge to manage the care a patient receiving perhexiline maleate treatment and provide a brief review of three new metabolic agents: trimetazidine, ranolazine and etomoxir...
  96. pmc Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise
    Robinson Joannides
    Department of Pharmacology, Rouen University Hospital, INSERM U644, Rouen, France
    Br J Clin Pharmacol 61:127-37. 2006
    ..To compare in humans the effects of ivabradine and propranolol on cardiac and systemic haemodynamics at rest, during tilt and exercise...
  97. ncbi Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?
    Gabor T Kovacs
    Haemato oncology Division, 2nd Department of Pediatrics, Semmelweis University, Tuzolto 7 9, 1094, Budapest, Hungary
    Eur J Pediatr 166:1187-8. 2007
  98. ncbi Does ranolazine have a place in the treatment of acute coronary syndromes?
    L Kristin Newby
    JAMA 297:1823-5. 2007
  99. ncbi Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up
    Lubomir Elbl
    Department of Cardiopulmonary Testing, University Hospital Brno, Jihlavska 20, Brno, 62500, Czech Republic
    Support Care Cancer 14:128-36. 2006
    ..The authors conducted a retrospective study to determine whether dexrazoxane (ICRF-187) would reduce late anthracycline-induced cardiotoxicity in patients treated in childhood for hematological malignancy...
  100. ncbi Loss of cardioprotection with ageing
    Kerstin Boengler
    Institut fur Pathophysiologie, Universitatsklinikum Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Cardiovasc Res 83:247-61. 2009
    ..g. ischaemic pre and postconditioning in aged organs and animals will be discussed, and the development of strategies aimed to antagonize the age-induced loss of protection will be addressed...
  101. ncbi Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution
    A R Sielecki
    Department of Biochemistry, University of Alberta, Edmonton, Canada
    Science 243:1346-51. 1989
    ..Knowledge of the actual structure, as opposed to the use of models based on related enzymes, should facilitate the design of renin inhibitors...

Research Grants96

  1. Organic Nitrate Metabolism, Tolerance and Action
    Ho Leung Fung; Fiscal Year: 2010
    ..believe that our studies can provide new and meaningful data that will contribute to the establishment of a unifying mechanism for organic nitrate action and deleterious effects, and lead to their better therapeutic use ..
  2. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2005
    ..The primary defense is replication: we would therefore welcome collaboration from others in the Pharmacogenetics Network in validation efforts. ..
  3. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2006
    ..The primary defense is replication: we would therefore welcome collaboration from others in the Pharmacogenetics Network in validation efforts. ..
  4. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2004
    ..The primary defense is replication: we would therefore welcome collaboration from others in the Pharmacogenetics Network in validation efforts. ..
  5. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2003
    ..The primary defense is replication: we would therefore welcome collaboration from others in the Pharmacogenetics Network in validation efforts. ..
  6. Impact of Medicaid Policy on cardiovascular drug use and clinical outcomes
    Michael A Fischer; Fiscal Year: 2010
    ....
  7. Metabolomics Network for Drug Response Phenotype
    RIMA F KADDURAH DAOUK; Fiscal Year: 2010
    ..Such knowledge can lead to more effective and personalized therapies. ..
  8. Metabolomics Network for Drug Response Phenotype
    Rima Kaddurah Daouk; Fiscal Year: 2009
    ..Such knowledge can lead to more effective and personalized therapies. ..
  9. Engineered tissue-based, high-throughput compound profiling
    Vy Lam; Fiscal Year: 2009
    ..This research may provide a breakthrough in accelerating drug discovery and reducing costs, because it is rapid, high-throughput, and may reduce the need for animal testing. ..
  10. Engineered tissue-based, high-throughput compound profiling
    VICTORIYA ALEKSANDROVNA RUFANOVA; Fiscal Year: 2010
    ..This research may provide a breakthrough in accelerating drug discovery and reducing costs, because it is rapid, high-throughput, and may reduce the need for animal testing. ..
  11. Heterocyclic Analogues of Podophyllotoxin Accessible by a One-Step Multicomponent
    Alexander Kornienko; Fiscal Year: 2009
    ..It involves the utilization of a naturally occurring plant metabolite, podophyllotoxin, for the design, preparation and testing of synthetic molecules expected to be toxic to cancer cells. ..
  12. CALCIUM ANTAGONISTS, AGING, AND HYPERTENSION
    Darrell Abernethy; Fiscal Year: 1990
    ..Furthermore an understanding of the pharmacodynamic uniqueness of each of the drugs as it relates to aging and hypertension will be developed...
  13. Organic Nitrate Metabolism, Tolerance and Action
    Ho Leung Fung; Fiscal Year: 2006
    ..can provide new and meaningful data that will contribute to the establishment of a unifying mechanism for organic nitrate action and deleterious effects, and lead to their better therapeutic use [unreadable] [unreadable] [unreadable]..
  14. Organic Nitrate Metabolism, Tolerance and Action
    Ho Leung Fung; Fiscal Year: 2009
    ..believe that our studies can provide new and meaningful data that will contribute to the establishment of a unifying mechanism for organic nitrate action and deleterious effects, and lead to their better therapeutic use ..
  15. Organic Nitrate Metabolism, Tolerance and Action
    Ho Leung Fung; Fiscal Year: 2007
    ..can provide new and meaningful data that will contribute to the establishment of a unifying mechanism for organic nitrate action and deleterious effects, and lead to their better therapeutic use [unreadable] [unreadable] [unreadable]..
  16. ETIOLOGY OF BLOOD DYSCRASIAS--ANALYSIS OF THE IAAAS DATA
    David Kaufman; Fiscal Year: 1990
    ..The proposed grant will enable the full scientific and public health benefits to be obtained from this unique resource, st a modest incremental cost...
  17. Atrial natriuretic peptide receptor crystallization
    Focco van den Akker; Fiscal Year: 2003
    ..Our long term structural studies on the molecular mechanism of ANP receptor signaling could enhance the development of renal and cardiovascular drugs. ..
  18. Atrial natriuretic peptide receptor crystallization
    Focco van den Akker; Fiscal Year: 2004
    ..Our long term structural studies on the molecular mechanism of ANP receptor signaling could enhance the development of renal and cardiovascular drugs. ..
  19. SEX STEROID HORMONES--EFFECTS ON DRUG CLEARANCE IN MAN
    Thomas Walle; Fiscal Year: 1990
    ..More generally, these studies will establish a solid base, in man as well as in animal and cell model systems, from which mechanistic studies on the influence of sex steroid hormones on drug clearance in man can be undertaken...
  20. Coupling mechanisms of OP4 receptor and calcium channels
    Victor Ruiz Velasco; Fiscal Year: 2005
    ..to clarify the signaling mechanisms underlying these processes and facilitate the development of novel cardiovascular agents for treating hypertension resulting from increased sympathetic tone...
  21. Coupling mechanisms of OP4 receptor and calcium channels
    Victor Ruiz Velasco; Fiscal Year: 2003
    ..to clarify the signaling mechanisms underlying these processes and facilitate the development of novel cardiovascular agents for treating hypertension resulting from increased sympathetic tone...
  22. Coupling mechanisms of OP4 receptor and calcium channels
    Victor Ruiz Velasco; Fiscal Year: 2004
    ..to clarify the signaling mechanisms underlying these processes and facilitate the development of novel cardiovascular agents for treating hypertension resulting from increased sympathetic tone...
  23. Coupling mechanisms of OP4 receptor and calcium channels
    Victor Ruiz Velasco; Fiscal Year: 2006
    ..to clarify the signaling mechanisms underlying these processes and facilitate the development of novel cardiovascular agents for treating hypertension resulting from increased sympathetic tone...
  24. SINGLE-CHAIN FV-PEPTIDE FUSION INHIBITOR OF FIBRIN CLOTS
    Mei Sheng Tai; Fiscal Year: 1991
    ..The data from these studies will permit a clear formulation of a Phase II project that can take full advantage of our expertise in the engineering of sFv fusion proteins...
  25. Assessment of a Telemetered PV-ECG System: Murine Models
    JUDITH GWATHMEY; Fiscal Year: 2004
    ..More comprehensive development and validation work will be carried out in a subsequent Phase 2 application. ..
  26. PHASE I/II STUDIES OF INVESTIGATIONAL AMINOQUINOLINES
    Donald Krogstad; Fiscal Year: 2000
    ..the association between changes in lipids and changes in the measurements; 4) to compare the use of cardiovascular agents and antidiabetic agents; 5) to compare survival and the incidence of angina pectoris, myocardial ..
  27. NEW MARINE SOURCES OF CARDIOVASCULAR AGENTS
    FREDERICK FUHRMAN; Fiscal Year: 1980
    ..Perfused rabbit ears would be used for study of vasodilator activity. We would attempt to determine chemical structure principally from mass and nmr spectral studies...
  28. PNEUMATIC ARTIFICIAL HEART STUDIES
    Don Olsen; Fiscal Year: 1980
    ..These include: cardiodynamics and hemodynamics at rest and exercise as influenced by cardiovascular agents; blood chemistry and hematologic parameters; blood coagulation kinetics and blood volume determinations; ..
  29. AUTOMATED HOME TABLET AND CAPSULE DISPENSER
    Thomas Shaw; Fiscal Year: 1990
    ..It also provides complete logging, is secure against theft and fully portable allowing for "pass medication."..
  30. AUTOMATED HOME TABLET AND CAPSULE DISPENSER
    Thomas Shaw; Fiscal Year: 1993
    ..It also provides complete logging, is secured against theft, and is fully portable, allowing for patient use during overnight or weekend visit...
  31. AUTOMATED HOME TABLET AND CAPSULE DISPENSER
    Thomas Shaw; Fiscal Year: 1992
    ..It also provides complete logging, is secured against theft, and is fully portable, allowing for patient use during overnight or weekend visit...
  32. SYNTHESIS OF THERAPEUTICALLY IMPORTANT ALKALOIDS
    Alan Kozikowski; Fiscal Year: 1980
    ..during these studies will be available for screening as potential prolactin inhibitors, antitumor and cardiovascular agents. Synthetic routes to the CNS active indolic compounds, the rugulovasines, will be examined based on a ..
  33. MODELS FOR BIOLOGICAL DATA RELEVANT TO HEALTH CARE
    Davide Verotta; Fiscal Year: 1999
    ....
  34. eNOS Polymorphisms, Aging and Platelet Function
    Jane Freedman; Fiscal Year: 2005
    ..We have continued to examine the imoortance of this mutation to the vascular response. ..
  35. eNOS Polymorphisms, Aging and Platelet Function
    Jane Freedman; Fiscal Year: 2004
    ..We have continued to examine the imoortance of this mutation to the vascular response. ..
  36. eNOS Polymorphisms, Aging and Platelet Function
    Jane Freedman; Fiscal Year: 2003
    ..We have continued to examine the imoortance of this mutation to the vascular response. ..
  37. eNOS Polymorphisms, Aging and Platelet Function
    Jane Freedman; Fiscal Year: 2002
    ..We have continued to examine the imoortance of this mutation to the vascular response. ..
  38. THYROID HORMONE AND CELLULAR CALCIUM REGULATION
    Laura Kragie; Fiscal Year: 1990
    ..dihydropyridine efficacy in (1) ameliorating symptoms associated with thyroid disorders and (2) as cardiovascular agents in patients with concombinant cardiovascular and thyroid disease...
  39. INTERDISCIPLINARY PROGRAM IN PHARMACOLOGY/TOXICOLOGY
    Thomas Gaffney; Fiscal Year: 1980
    ..This research is done by an integrated and interdisciplinary group of biochemical, physiological and clinical pharmacologists, chemists, cardiologists, radiologists, endocrinologists, biometricians, pharmacists and pathologists...
  40. EFFECT OF SYSTEMIC DRUGS ON TEAR PRODUCTION
    MICHAEL LEMP; Fiscal Year: 1980
    ..taken by millions of patients with diverse disease (antihistamines, antispasmodics, anti-Parkinson drugs, cardiovascular agents, psychotropic drugs) have anticholinergic effects and seem to have an adverse effect on tear production...
  41. MD & PATIENT ACCEPTANCE OF MICROPROCESSOR DRUG DISPENSER
    ESTHER KLAY; Fiscal Year: 1990
    ..e., cardiovascular drugs, asthmatics, antidepressants, etc.). Additional applications could include monitoring, accounting for and controlling narcotics in the hospital and use in clinical trials for investigational agents...
  42. OLDER PERSONS AND DRUGS--CALCIUM BLOCKER KINETICS/DYNAMICS
    JANICE SCHWARTZ; Fiscal Year: 1999
    ..abstract_text> ..
  43. Inhibitors of PAR1-G13 Interface for Arthersclerosis
    Annette Gilchrist; Fiscal Year: 2002
    ..Hundreds of billions of dollars are spent each year treating heart disease. In 1998, it was estimated that sales of cardiovascular drugs alone were $37 billion. ..
  44. Hypertension Pharmacogenetics
    Julie Johnson; Fiscal Year: 2006
    ..The proposed studies should add substantial new information about antihypertensive pharmacogenetics, and could influence how antihypertensive medications are prescribed in the future. ..
  45. Beta-receptors and cardiovascular pharmacogenomics
    Julie Johnson; Fiscal Year: 2006
    ..abstract_text> ..
  46. Hypertension Pharmacogenetics
    Julie Johnson; Fiscal Year: 2003
    ..The proposed studies should add substantial new information about antihypertensive pharmacogenetics, and could influence how antihypertensive medications are prescribed in the future. ..
  47. BETA-ADRENERGIC RECEPTOR POLYMORPHISMS AND HYPERTENSION
    Julie Johnson; Fiscal Year: 2001
    ..the BAR genotype significantly impacts the BP response to B-blockers could lead to improved patient outcomes, as patients could be genotyped prior to institution of B-blocker therapy, thus avoiding this therapy in those likely to respond ..
  48. Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors
    Steven Lipshultz; Fiscal Year: 2008
    ..If the HFE mutations are related to increased cardiotoxicity of anthracyclines. This study will elucidate the molecular mechanisms of anthracycline cardiotoxicity in pediatric ALL cancer survivors. ..
  49. HAART Associated Cardiotoxicity in HIV-Infected Children
    Steven Lipshultz; Fiscal Year: 2007
    ..The findings will help determine the need for cardiovascular follow-up, prevention and therapeutic trials. ..
  50. PEDIATRIC CARDIOMYOPATHY REGISTRY
    Steven Lipshultz; Fiscal Year: 2000
    ..The registry should lead to definitive understanding of the pathogenesis of these disorders and offer the hope to have a major clinical impact on the clinical practice of medicine in this area. ..
  51. PEDIATRIC CARDIOMYOPATHY REGISTRY
    Steven Lipshultz; Fiscal Year: 2003
    ..abstract_text> ..
  52. Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors
    Steven Lipshultz; Fiscal Year: 2007
    ..If the HFE mutations are related to increased cardiotoxicity of anthracyclines. This study will elucidate the molecular mechanisms of anthracycline cardiotoxicity in pediatric ALL cancer survivors. ..
  53. PEDIATRIC CARDIOMYOPATHY REGISTRY
    Steven Lipshultz; Fiscal Year: 2005
    ..These studies will dramatically increase our understanding of pediatric cardiomyopathy, suggest new areas of research and improved patient management. ..
  54. Cardiovascular Status of HAART-Exposed Infants/Children
    Steven Lipshultz; Fiscal Year: 2003
    ..This study will determine the cardiovascular effects of HAART in seroreverters and the need for future cardiovascular follow-up and cardiovascular preventive and therapeutic trials in this rapidly expanding population. ..
  55. PEDIATRIC CARDIOMYOPATHY REGISTRY
    Steven Lipshultz; Fiscal Year: 2007
    ..These studies will dramatically increase our understanding of pediatric cardiomyopathy, suggest new areas of research and improved patient management. ..
  56. Cardiovascular Status of HAART-Exposed Infants/Children
    Steven Lipshultz; Fiscal Year: 2003
    ..This study will determine the cardiovascular effects of HAART in seroreverters and the need for future cardiovascular follow-up and cardiovascular preventive and therapeutic trials in this rapidly expanding population. ..
  57. POTASSIUM CHANNELS AND CEREBRAL HEMODYNAMICS AFTER BRAIN
    William Armstead; Fiscal Year: 2000
    ..These studies may lead to therapies for brain injured children. ..
  58. Plasminogen activators and NMDA after brain injury
    William Armstead; Fiscal Year: 2009
    ..Immunohistochemistry, detection of plasminogen activator and MAPK expression, and CBF determination by radiolabled microspheres will be performed. ..
  59. Plasminogen activators and NMDA after brain injury
    William Armstead; Fiscal Year: 2008
    ..Immunohistochemistry, detection of plasminogen activator and MAPK expression, and CBF determination by radiolabled microspheres will be performed. ..
  60. Plasminogen activators and NMDA after brain injury
    William M Armstead; Fiscal Year: 2010
    ..Immunohistochemistry, detection of plasminogen activator and MAPK expression, and CBF determination by radiolabled microspheres will be performed. ..
  61. POTASSIUM CHANNELS AND CEREBRAL HEMODYNAMICS AFTER BRAIN
    William Armstead; Fiscal Year: 2005
    ..These studies may lead to therapies for brain injured children. ..
  62. Plasminogen activators and cerebral ischemic injury
    William M Armstead; Fiscal Year: 2010
    ....
  63. POTASSIUM CHANNELS AND CEREBRAL HEMODYNAMICS AFTER BRAIN
    William Armstead; Fiscal Year: 2003
    ..These studies may lead to therapies for brain injured children. ..
  64. POTASSIUM CHANNELS AND CEREBRAL HEMODYNAMICS AFTER BRAIN
    William Armstead; Fiscal Year: 2002
    ..These studies may lead to therapies for brain injured children. ..
  65. Plasminogen activators and cerebral ischemic injury
    William Armstead; Fiscal Year: 2007
    ....
  66. Epoxyeicosanoids and Renal Vascular Function in Obesity & Hypertension
    JOHN IMIG; Fiscal Year: 2008
    ..On the whole, the proposed experiments in this application will provide novel insight and therapeutic targets for the treatment of chronic kidney disease in obesity and hypertension. ..
  67. CASE CONTROL STUDY OF INSOMNIA IN NONDEPRESSED ELDERLY
    Allan Pack; Fiscal Year: 1999
    ....
  68. EPIDEMIOLOGY OF CARDIOVASCULAR RISK FACTORS IN WOMEN
    Lewis Kuller; Fiscal Year: 1992
    ..They state that it has become the cornerstone of a major research effort in women's health...
  69. PATHOGENESIS OF TRANSPLANT ASSOCIATED ARTERIOSCLEROSIS
    Peter Libby; Fiscal Year: 1999
    ..The observations point to distinct mechanisms mediating acute vs. chronic allograft pathologies, and suggest that different therapeutic interventions will be uniquely applicable to each. ..
  70. Training Program in Sleep and Respiratory Neurobiology
    Allan Pack; Fiscal Year: 2008
    ..The training program includes structures to help with grant writing and provides career counseling. There is an active minority recruitment program with minority investigators collaborating with the Program Directors in this effort. ..
  71. Training Grant in Cardiovascular Research
    Peter Libby; Fiscal Year: 2008
    ..In this application we propose to continue our longstanding record (documented within) or preparing a talented pool of fellows for successful academic careers. ..
  72. Comprehensive Laboratory Animal Monitoring System
    Martin Young; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  73. Molecular Circadian Clock within the Heart
    Martin Young; Fiscal Year: 2004
    ..Our long-term goals are to establish the molecular mechanisms and physiological role(s) of the circadian clock within the heart, and to determine the pathophysiological consequences of impairment of this mechanism. ..
  74. PATHOGENESIS OF TRANSPLANT ASSOCIATED ARTERIOSCLEROSIS
    Peter Libby; Fiscal Year: 2002
    ..The observations point to distinct mechanisms mediating acute vs. chronic allograft pathologies, and suggest that different therapeutic interventions will be uniquely applicable to each. ..
  75. EPIDEMIOLOGY OF CARDIOVASCULAR RISK FACTORS IN WOMEN
    Lewis Kuller; Fiscal Year: 2002
    ..They further note that the identification of early and modifiable risk factors for subclinical disease should lead to prevention or reduction of clinical cardiovascular disease among postmenopausal women. ..
  76. REDUCTION OF TRIGLYCERIDES IN WOMEN ON HRT
    Lewis Kuller; Fiscal Year: 2005
    ..NMR spectroscopy of lipoproteins, inflammatory markers, and estrogen metabolites will also be evaluated. Therefore, the primary goal of this trial is the modification of measures of subclinical disease among HRT users. ..
  77. MECHANISMS OF RENAL PROSTAGLANDIN TRANSPORT
    VICTOR SCHUSTER; Fiscal Year: 2002
    ..5. Examine regulation of PGT expression in the rat kidney in vivo following maneuvers that alter PGE2 production and release. ..
  78. Role of the Molecular Circadian Clock within the Heart
    Martin Young; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  79. Cytokines and Sympathetic Activation in Heart Failure
    Robert Felder; Fiscal Year: 2006
    ..These studies will provide new insights into the role of the pro-imflammatory cytokines in heart failure, perhaps leading to new therapeutic strategies. ..
  80. Role of the Molecular Circadian Clock within the Heart
    Martin Young; Fiscal Year: 2008
    ..Our long-term objectives are to establish causal links between impairment of the circadian clock within the cardiomyocyte with development of CV disease in humans. ..
  81. Northeast Ohio Center for Cardiovascular Cell Therapy Research
    Stephen Ellis; Fiscal Year: 2008
    ..abstract_text> ..
  82. Family Linkage Study of Obstructive Sleep Apnea
    Allan Pack; Fiscal Year: 2003
    ..abstract_text> ..
  83. MECHANISMS OF RENAL PROSTAGLANDIN TRANSPORT
    VICTOR SCHUSTER; Fiscal Year: 2001
    ..5. Examine regulation of PGT expression in the rat kidney in vivo following maneuvers that alter PGE2 production and release. ..
  84. Northeast Ohio Center for Cardiovascular Cell Therapy Research
    Stephen Ellis; Fiscal Year: 2007
    ..End of Abstract) [unreadable] [unreadable] [unreadable]..
  85. PHOSPHOLIPASE C AND CARDIAC HYPERTROPHY
    GERALD DORN; Fiscal Year: 1999
    ..In addition it is likely that new therapies, targeted toward specific signal transducers or effectors, will result from these studies. ..